Furthermore, bexarotene, an RXR agonist, which restores ciliogenesis in ccRCC cells devoid of VHL in a mechanism involving AURKA reduction, attenuates incidence of ccRCC tumor xenografts in mice [177]. The gene discussed is AURKA; the disease is nonpapillary renal cell carcinoma.